Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma

Cancer Letters

Volumn 369, Issue 1, 2015, Pages 250-258

  Kim, Sang Soo ^a   Rait, Antonina ^a   Kim, Eric ^b   DeMarco, James ^b   Pirollo, Kathleen F ^a   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b SynerGene Therapeutics Inc   (United States)

Author keywords

Cancer stem cells; Glioblastoma multiforme; Nanocomplex; Targeted delivery; Temozolomide resistance

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; DIOLEOYLPHOSPHATIDYL ETHANOLAMINE; LIPOSOME; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DACARBAZINE; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; FEMALE; GENETIC TRANSFECTION; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NANOMEDICINE; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; TUMOR CELL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DACARBAZINE; FEMALE; GLIOBLASTOMA; HUMANS; MICE, NUDE; NANOCAPSULES; TREATMENT OUTCOME; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84943455550     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.08.022     Document Type: Article

References (36)

1. Nagasawa D.T., et al. Temozolomide and other potential agents for the treatment of glioblastoma multiforme. Neurosurg. Clin. N. Am 2012, 23:307-322. ix.
2. Chamberlain M.C. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev. Neurother 2010, 10:1537-1544.
3. Ramirez Y.P., Weatherbee J.L., Wheelhouse R.T., Ross A.H. Glioblastoma multiforme therapy and mechanisms of resistance. Pharmaceuticals (Basel) 2013, 6:1475-1506.
4. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol. Cancer 2011, 10:128.
5. Berrocal A., et al. Extended-schedule dose-dense temozolomide in refractory gliomas. J. Neurooncol 2010, 96:417-422.
6. Kim S.S., et al. A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival. ACS Nano 2014, 8:5494-5514.
7. Kim S.S., Rait A., Kim E., Pirollo K.F., Chang E.H. A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme. Nanomedicine 2015, 11:301-311.
8. Pirollo K.F., et al. p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy. Oncogene 1997, 14:1735-1746.
9. Pirollo K.F., et al. Tumor-targeting nanocomplex delivery of novel tumor suppressor RB94 chemosensitizes bladder carcinoma cells in vitro and in vivo. Clin. Cancer Res 2008, 14:2190-2198.
10. Rait A.S., Pirollo K.F., Xiang L., Ulick D., Chang E.H. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol. Med 2002, 8:475-486.
11. Xu L., Pirollo K.F., Chang E.H. Tumor-targeted p53-gene therapy enhances the efficacy of conventional chemo/radiotherapy. J. Control. Release 2001, 74:115-128.
12. Xu L., Pirollo K.F., Tang W.H., Rait A., Chang E.H. Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther 1999, 10:2941-2952.
13. Senzer N., et al. Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. Mol. Ther 2013, 21:1096-1103.
14. Daniels T.R., Delgado T., Helguera G., Penichet M.L. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol 2006, 121:159-176.
15. Jones A.R., Shusta E.V. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res 2007, 24:1759-1771.
16. Ulbrich K., Hekmatara T., Herbert E., Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm 2009, 71:251-256.
17. Pardridge W.M., Boado R.J. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012, 503:269-292.
18. Dufes C., Al Robaian M., Somani S. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells. Ther. Deliv 2013, 4:629-640.
19. Kreuter J. Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB). J. Microencapsul 2013, 30:49-54.
20. Kohsaka S., et al. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol. Cancer Ther 2012, 11:1289-1299.
21. Xu L., et al. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther 2002, 1:337-346.
22. Yu W., et al. Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res 2004, 32:e48.
23. Teicher B.A., et al. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin. Cancer Res 2001, 7:634-640.
24. Yang W., et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol 2012, 14:1295-1304.
25. Zhu W., et al. Temozolomide for treatment of brain metastases: a review of 21 clinical trials. World J. Clin. Oncol 2014, 5:19-27.
26. Tatar Z., et al. Temozolomide and unusual indications: review of literature. Cancer Treat. Rev 2013, 39:125-135.
27. Xu L., et al. Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFv. Mol. Med 2001, 7:723-734.
28. Huang G., Zhang N., Bi X., Dou M. Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int. J. Pharm 2008, 355:314-320.
29. Sengupta S., Marrinan J., Frishman C., Sampath P. Impact of temozolomide on immune response during malignant glioma chemotherapy. Clin. Dev. Immunol 2012, 2012:831090.
30. Yu W., et al. A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene. Gene Ther 2004, 11:1434-1440.
31. Xu L., et al. Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. Hum. Gene Ther 2002, 13:469-481.
32. Yang C., et al. Nanoimmunoliposome delivery of superparamagnetic iron oxide markedly enhances targeting and uptake in human cancer cells in vitro and in vivo. Nanomedicine 2008, 4:318-329.
33. Chou C.W., et al. Tumor cycling hypoxia induces chemoresistance in glioblastoma multiforme by upregulating the expression and function of ABCB1. Neuro-Oncol 2012, 14:1227-1238.
34. Juillerat-Jeanneret L. The targeted delivery of cancer drugs across the blood-brain barrier: chemical modifications of drugs or drug-nanoparticles?. Drug Discov. Today 2008, 13:1099-1106.
35. Noell S., Mayer D., Strauss W.S., Tatagiba M.S., Ritz R. Selective enrichment of hypericin in malignant glioma: pioneering in vivo results. Int. J. Oncol 2011, 38:1343-1348.
36. Tentori L., Graziani G. Recent approaches to improve the antitumor efficacy of temozolomide. Curr. Med. Chem 2009, 16:245-257.